Remember that this is the first P3 trial EVER and ANYWHERE for Phelan-McDermid syndrome.
Synchronicity regarding efficacy endpoints with the FDA is paramount for optimal rigour in the trial.
Much, much better to do this face to face in a Type C meeting so everything is crystal clear, transparent and explicitly outlined.
Then the Magnificent NNZ-2591 will just get on and do the business as we know it will.
Remember that this is the first P3 trial EVER and ANYWHERE for...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |